Allorion Therapeutics Entered Into Exclusive Option And Global License Agreement With AstraZeneca To Develop And Commercialize Epidermal Growth Factor Receptor L858R Mutated Allosteric Inhibitor, As Potential New Treatment For Advanced EGFR-Mutant NSCLC
Portfolio Pulse from Benzinga Newsdesk
Allorion Therapeutics has entered into an agreement with AstraZeneca for the development and global commercialization of an EGFR L858R allosteric inhibitor, aimed at treating advanced EGFR-Mutant NSCLC. AstraZeneca has an exclusive option to license this inhibitor. Allorion could receive up to $40 million in upfront and near-term payments, over $500 million in milestone payments, and royalties on worldwide net sales.
January 02, 2024 | 2:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AstraZeneca has secured an exclusive option to license a novel EGFR inhibitor from Allorion Therapeutics, with potential payments exceeding $540 million plus royalties.
The agreement with Allorion Therapeutics could potentially add a significant new product to AstraZeneca's portfolio, which is likely to be viewed positively by investors. The financial commitment suggests confidence in the inhibitor's prospects, which may lead to a short-term positive impact on AstraZeneca's stock price.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80